Products and
Pipeline

Overview¹

TAK-007 (SFG.iC9.2A.CAR.CD19-28-3zeta.2A.IL15) is a CD19 chimeric antigen receptor-directed cord blood derived natural killer (CAR-NK) cell therapy

MOA^2-4

- A retrovirus is used to introduce new genes into NK cells derived from cord blood

- CD19 is added to increase the CAR NK specificity for B-cell malignancies

- IL15 is added to prolong the survival and proliferation of the NK cells in the recipient

- A CASP9-based “safety switch” (iCas9-IL15) is introduced to allow triggering of apoptosis of the allogenic NK cells if required after infusion

- Cord blood offers an allogeneic, off-the-shelf source of NK cells. NK cells are highly cytotoxic effectors, killing their targets in a non-antigen specific manner without causing GvHD. These characteristics might be able to overcome some of the drawbacks of currently available CAR T cell therapies

Clinical Trials

Study Name

Dose Escalation Study Phase l/ll of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies

References

1. Takeda press release, Nov 2019. Available at: www.takeda.com (accessed Nov 2019).

2. Daher M, Rezvani K. Curr Opin Immunol. 2018;51:146-153.

3. Liu E, et al. Leukemia. 2018;32:520-531.

4. Liu E, et al. N Engl J Med. 2020;382:545-553.

Disclaimers

*Under licensing agreement and in collaboration with MD Anderson Cancer Center.